Seaport Therapeutics Holds $403.8 Million, Enough Cash to Run Into 2029
Seaport Therapeutics ended Q3 with $403.8 million in cash, up 73% since December, and says it is funded into 2029. Its net loss widened 17% to $26.4 million.
Boston biotech